{"id":"NCT03926130","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-23","primaryCompletion":"2023-08-23","completion":"2023-10-02","firstPosted":"2019-04-24","resultsPosted":"2024-12-27","lastUpdate":"2024-12-27"},"enrollment":1158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Mirikizumab","otherNames":["LY3074828"]},{"type":"DRUG","name":"Mirikizumab","otherNames":["LY3074828"]},{"type":"DRUG","name":"Ustekinumab","otherNames":[]},{"type":"DRUG","name":"Ustekinumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"300 mg Mirikizumab","type":"EXPERIMENTAL"},{"label":"90 mg Ustekinumab","type":"ACTIVE_COMPARATOR"},{"label":"300 mg Mirikizumab (Adolescents)","type":"EXPERIMENTAL"}],"summary":"The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.","primaryOutcome":{"measure":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)","timeFrame":"Week 12 to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":9,"sd":null},{"arm":"Mirikizumab","deltaMin":38,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.000001"}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":580,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Croatia","Czechia","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40669578","40491246","40079470","39962027","39692838","39581202","39537976"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/LRPzbNMzQDQDgtgTZPJMQ"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":211},"commonTop":["Covid-19","Anaemia","Upper respiratory tract infection","Nasopharyngitis","Headache"]}}